

Please try another search
Mersana Therapeutics, Inc. (MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...
Mersana Therapeutics (MRSN) Halted, News Pending
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of...
Investing.com - Mersana Therapeutics (NASDAQ: MRSN) reported fourth quarter EPS of $-0.44, $0.05 better than the analyst estimate of $-0.49. Revenue for the quarter came in at $14.69M versus the...
Mersana Therapeutics (NASDAQ:MRSN) reported Q4 EPS of ($0.44), $0.05 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $14.69 million versus the consensus estimate of...
By Investing.com Staff After-hours stock movers: Mission Produce (NASDAQ:AVO) 14% LOWER; reported Q4 EPS of $0.13, $0.21 worse than the analyst estimate of $0.34. Revenue for the quarter came in at...
(Reuters) - Mersana Therapeutics (NASDAQ:MRSN) Inc said on Thursday it had signed a deal for developing cancer drugs with Germany's Merck KGaA that has the potential to generate up to $800 million in...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review